(Q44755180)

English

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

scientific article published on 13 March 2013

In more languages
default for all languages
No label defined

No description defined

Statements

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours (English)
Rastislav Bahleda
Jean-Pierre Armand
Frances A Shepherd
Christopher T Harbison
Blisse Vakkalagadda

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit